| Updated efficacy analysis including secondary population results for OAK: a randomized phase III study of atezolizumab versus docetaxel in patients with previously treated … L Fehrenbacher, J von Pawel, K Park, A Rittmeyer, DR Gandara, SP Aix, ... Journal of thoracic oncology 13 (8), 1156-1170, 2018 | 241 | 2018 |
| Excitotoxicity downregulates TrkB. FL signaling and upregulates the neuroprotective truncated TrkB receptors in cultured hippocampal and striatal neurons JR Gomes, JT Costa, CV Melo, F Felizzi, P Monteiro, MJ Pinto, AR Inácio, ... Journal of Neuroscience 32 (13), 4610-4622, 2012 | 116 | 2012 |
| Patient-reported outcomes in OAK: a phase III study of atezolizumab versus docetaxel in advanced non–small-cell lung cancer R Bordoni, F Ciardiello, J von Pawel, D Cortinovis, T Karagiannis, ... Clinical Lung Cancer 19 (5), 441-449. e4, 2018 | 72 | 2018 |
| Machine learning methods in health economics and outcomes research—the PALISADE checklist: a good practices report of an ISPOR task force WV Padula, N Kreif, DJ Vanness, B Adamson, JD Rueda, F Felizzi, ... Value in health 25 (7), 1063-1080, 2022 | 34 | 2022 |
| Mixture cure models in oncology: a tutorial and practical guidance F Felizzi, N Paracha, J Pöhlmann, J Ray PharmacoEconomics-open 5, 143-155, 2021 | 31 | 2021 |
| Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC) U Ondhia, HJ Conter, S Owen, A Zhou, J Nam, S Singh, A Abdulla, P Chu, ... Journal of medical economics 22 (7), 625-637, 2019 | 26 | 2019 |
| Analyzing and constraining signaling networks: parameter estimation for the user F Geier, G Fengos, F Felizzi, D Iber Computational modeling of signaling networks, 23-39, 2012 | 24 | 2012 |
| Cost-effectiveness of atezolizumab versus docetaxel and nivolumab in the treatment of non-small cell lung cancer as a second line in France S Marine, R Stéphane, P Nicolas, F Felizzi, N Paracha, M Benjamin, ... Journal of Medical Economics 23 (5), 464-473, 2020 | 13 | 2020 |
| US cost–effectiveness of polatuzumab vedotin, bendamustine and rituximab in diffuse large B-cell lymphoma KA Betts, PO Thuresson, F Felizzi, EX Du, I Dieye, J Li, M Schulz, ... Journal of comparative effectiveness research 9 (14), 1003-1015, 2020 | 10 | 2020 |
| ESTIMATION OF LONG‐TERM SURVIVAL WITH POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB FOR PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (R/R DLBCL) LH Sehn, C Flowers, A McMillan, F Morschhauser, G Salles, F Felizzi, ... Hematological Oncology 37, 257-258, 2019 | 9 | 2019 |
| A social media listening study to understand the unmet needs and quality of life in adult and pediatric amblyopia patients A Syntosi, F Felizzi, C Bouchet Ophthalmology and Therapy 11 (6), 2183-2196, 2022 | 6 | 2022 |
| Integrin clustering as a result of local membrane deformations and local signaling feedbacks F Felizzi, D Iber Physica A: Statistical Mechanics and its Applications 408, 198-211, 2014 | 4 | 2014 |
| Network-of-queues approach to B-cell-receptor affinity discrimination F Felizzi, F Comoglio Physical Review E 85 (6), 061926, 2012 | 4 | 2012 |
| Efficacy and safety of brolucizumab, aflibercept, and ranibizumab for the treatment of patients with visual impairment due to diabetic macular oedema: a systematic review and … S Sydnor, S Chatterjee, P Cooney, S Kaur, T Macmillan, D Stewart, ... Diabetes Therapy 14 (7), 1193-1216, 2023 | 3 | 2023 |
| Patient-reported outcomes (PROs) in OAK: a phase III study of atezolizumab vs docetaxel in non-small-cell lung cancer (NSCLC) R Bordoni, F Ciardiello, J Von Pawel, D Cortinovis, P He, T Karagiannis, ... Journal of Thoracic Oncology 12 (11), S1913-S1914, 2017 | 3 | 2017 |
| Rate of hospitalization due to adverse event and length of stay for atezolizumab in second and third line metastatic non-small lung cancer (NSCLC) using phase 3 Oak study N Paracha, F Felizzi Value in Health 20 (9), A447, 2017 | 3 | 2017 |
| Approximation of Long-Term Survival with Polatuzumab Vedotin Plus Bendamustine and Rituximab for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results Based … F Felizzi, A Launonen, PO Thuresson PharmacoEconomics-Open 7 (1), 37-46, 2023 | 2 | 2023 |
| EE405 A UK Cost-minimisation analysis of brolucizumab versus aflibercept in diabetic macular oedema (DMO) S Sydnor, M Ibrahim, I Singh, U Vudumula, L Marshall, E Hancock, ... Value in Health 25 (12), S135, 2022 | 2 | 2022 |
| Semiparametric estimation of the cure fraction in population‐based cancer survival analysis E Gu, J Zhang, W Lu, L Wang, F Felizzi Statistics in Medicine 39 (26), 3787-3805, 2020 | 2 | 2020 |
| felizzi/Cure_models: Cure_models_tutorial (Version v1. 0). Zenodo J Poehl | 2 | 2018 |
Noman ParachaVerified email at bayer.com
